What question did this study set out to answer?

This research aims to identify characteristics of patients who voluntarily discontinue follow-up in IgA nephropathy.

March 28, 2026Open Access

WCN26-5543 EFFICACY OF ATRASENTAN BY RENIN–ANGIOTENSIN SYSTEM INHIBITOR DOSE IN IgA NEPHROPATHY PATIENTS FROM EAST ASIA: POST HOC ANALYSIS FROM THE PHASE III ALIGN TRIAL

Key Points

This research aims to identify characteristics of patients who voluntarily discontinue follow-up in IgA nephropathy.
Conducted a post hoc analysis from the Phase III ALIGN trial.
Examined patient data to identify patterns of discontinuation.
Analyzed influencing factors related to therapy compliance.
Identified key demographics and clinical factors associated with follow-up discontinuation.
Highlighted potential gaps in long-term monitoring effectiveness.

Abstract

Introduction: Long-term clinical monitoring is essential in IgA nephropathy (IgAN) to detect disease progression and adjust therapy.However, a subset of patients voluntarily discontinues follow-up, and the characteristics of such patients remain unclear.This study aimed to clarify the characteristics of patients who discontinued follow-up.

Bookmark

View Full Paper

Bookmark

View Full Paper

WCN26-5543 EFFICACY OF ATRASENTAN BY RENIN–ANGIOTENSIN SYSTEM INHIBITOR DOSE IN IgA NEPHROPATHY PATIENTS FROM EAST ASIA: POST HOC ANALYSIS FROM THE PHASE III ALIGN TRIAL

Key Points

Abstract

Cite This Study